Skip to Content

Xadago Approval Status

  • FDA approved: No
  • Brand name: Xadago
  • Generic name: safinamide
  • Company: Newron Pharmaceuticals S.p.A.
  • Treatment for: Parkinson's Disease

Xadago (safinamide) is an alpha-aminoamide in development as an add-on therapy to dopamine agonists or to levodopa in patients with early or mid- to late-stage Parkinson’s disease.

Development Status and FDA Approval Process for Xadago

Oct 21, 2016US FDA Considers Newron’s Re-Submitted NDA for Xadago to be a Complete, Class 2 Response to Complete Response Letter
Sep 22, 2016Newron Re-Submits US NDA for Xadago (safinamide)
Jul 26, 2016Newron to Re-Submit US NDA for Xadago (safinamide)
Mar 29, 2016Newron Receives Complete Response Letter from US FDA for Xadago (safinamide)
Sep 30, 2015Xadago (safinamide) NDA Late-Cycle Review Meeting Completed with U.S. FDA
Mar  2, 2015Xadago (safinamide) NDA Accepted for Filing by the U.S. FDA
Dec 29, 2014Safinamide NDA Re-submitted to the U.S. FDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.